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Abstract: 55 
 56 
BACKGROUND/AIMS : To evaluate the vitreous signals obtained on spectral 57 
domain optical coherence tomography (SD-OCT) in patients with uveitic cystoid 58 
macular oedema (CMO) and compare these signals before and after sub-Tenon’s 59 
triamcinolone acetonide injection.  60 
METHODS 61 
Design: Retrospective study with standardised longitudinal imaging pre- and post-62 
intervention.  The study cohort comprises 22 patients (22 eyes) with uveitic CMO 63 
receiving a Sub-Tenon’s Triamcinolone Acetonide (STTA) injection. Post-hoc 64 
analysis of SD-OCT images using custom software provided an “absolute” 65 
measurement of vitreous signal intensity, which was expressed as a ratio to the 66 
retinal pigment epithelium intensity (“VIT/RPE-relative intensity”) in arbitrary units.  67 
Main Outcome Measure: Difference in VIT/RPE-relative intensity before and after 68 
treatment.  69 
RESULTS:  Treatment with STTA resulted in a significant reduction in VIT/RPE-70 
Relative Intensity, which was associated with both a reduction in central retinal 71 
thickness (CRT) and improvement in visual acuity. Mean (SD) VIT/RPE-Relative 72 
Intensity pre-treatment was 0.139 (0.074) vs. 0.053 (0.028) post-treatment (p=3x10-73 
5). Mean (SD) CRT was 581μm (119μm) pre-treatment vs 333μm (95μm) post-74 
treatment (p=2x10-8); the mean reduction in CRT was 248 (95%CI: 189-306). The 75 
correlation coefficient between VIT/RPE-Relative Intensity and CRT was 0.534 76 
(p=0.011) and between VIT/RPE-Relative Intensity and visual acuity was 0.702 77 
(p=0.0001). 78 
CONCLUSION: This study provides evidence that the OCT-derived VIT/RPE-79 
Relative intensity may be useful as a quantitative and objective marker of disease 80 
activity and treatment response in uveitis complicated by CMO. This first longitudinal 81 
study of this novel OCT parameter is an encouraging step in the development of 82 
sensitive objective OCT-based endpoints for trials of efficacy in uveitis. 83 
 84 
  85 
Introduction 86 
 87 
Uveitis, a group of conditions characterised by intraocular inflammation, is a 88 
major cause of blindness worldwide (1). The commonest cause of sight loss in uveitis 89 
is cystoid macular oedema (CMO), which accounts for around a third of blindness 90 
caused by the disease (2). CMO may be reversible with prompt corticosteroid 91 
treatment (3) such as with Sub-Tenon’s triamcinolone acetonide (STTA), leading to 92 
visual recovery (4-6).   93 
Vitreous inflammation can be seen on examination as a characteristic “haze”, 94 
caused by the presence of proteinaceous exudate in the vitreous. The level of 95 
vitreous haze is considered to be a good marker of inflammation in the underlying 96 
uveal tract. For this reason the National Eye Institute (NEI) “Vitreous Haze Score” is 97 
the trial endpoint most commonly accepted by regulatory bodies. The NEI scale is 98 
determined by examining the vitreous using an indirect ophthalmoscope with 99 
comparison to standardised photographs. Weaknesses are that it is subjective, non-100 
continuous, poorly discriminatory at lower levels of inflammation and has low 101 
sensitivity in a clinical trial context (7-10).  102 
 Optical coherence tomography (OCT), an imaging modality that provides high 103 
resolution, cross sectional images of ocular tissues non-invasively is well-established 104 
in the measurement of macular pathology, including macular oedema (11-13). Most 105 
analysis of OCT images is qualitative, but quantitative analysis  - such as the 106 
measurement of central macular thickness in macular oedema – provides an 107 
objective and sensitive measure of deviation from normal, change over time and 108 
response to therapy. We and others are using these principles to develop measures 109 
all the key components of intraocular inflammation, such that the clinical assessment 110 
of uveitis may become more objective and reliable (8, 14-18). We have shown in two 111 
independent cohorts using two different OCT-platforms that measurements of 112 
vitreous inflammation derived from OCT scans are repeatable, reliable and 113 
correlated with clinical measures of disease activity, notably  the NEI Vitreous Haze 114 
Score (17-18). To help ensure internal standardisation, we utilised the reflective 115 
intensity of the retinal pigment epithelium (RPE) as a reference, thereby producing a 116 
ratio (“VIT/RPE-Relative Intensity) (17-18)..  117 
 The aim of this paper is to further validate the use of the VIT/RPE-Relative 118 
Intensity as a marker of disease activity in uveitis by assessing whether it is capable 119 
of detecting changes in the vitreous pre-/post-STTA, and whether these correlate 120 
with other signs of reduction in disease activity.  121 
 122 
  123 
Materials and Methods 124 
 125 
Study Population: 126 
 This is a retrospective, longitudinal study comprising 22 patients with uveitic CMO 127 
attending a tertiary uveitis clinic at the Birmingham & Midlands Eye Centre, Sandwell 128 
& West Birmingham Hospitals NHS Trust, United Kingdom. All patients had a 129 
complete ophthalmic assessment including visual acuity, slit lamp examination, 130 
grading of anterior chamber inflammation, intraocular pressure measurement, fundus 131 
examination and grading of vitreous inflammation using the NEI Vitreous Haze 132 
Score. Approval for data collection and analysis was obtained from a U.K. National 133 
Health Service research ethics committee and adhered to the tenets set forth in the 134 
Declaration of Helsinki. All patients were consented for posterior STTA 135 
administration.  136 
 137 
Procedure: 138 
Povidone iodine and oxybuprocaine drops were used to sterilize and anesthetize the 139 
eye before the procedure. The conjunctiva and sub-Tenons layer were lifted 10mm 140 
from the limbus superotemporally using blunt serrated forceps. The sub-Tenon’s 141 
cannula was attached to a 2ml syringe containing 1ml of 40mg/ml triamcinolone 142 
acetonide, and inserted, advancing the needle 12-14mm into the posterior sub-143 
Tenons space into which the full dose (i.e. 40mg triamcinolone acetonide) was 144 
administered (19).  145 
 146 
Image Acquisition: 147 
Optical coherence tomographic image sets were obtained using Heidelberg 148 
Spectralis OCT (Heidelberg Engineering, Germany). The images were obtained 149 
immediately prior to the procedure and at the first subsequent clinical review. The 150 
volume scan images were centred on the fovea and the TruTrack Active and 151 
AutoRescan features were used to ensure that follow-up scans were matched to the 152 
baseline scan.. The enhanced depth protocol was not used.  153 
 154 
Quantitative Assessment of Vitreous Signal Intensity: 155 
As per our previously published protocol, OCT scan images were imported into 156 
‘OCTOR’, a program for easy navigation and manual grading of the scans validated 157 
in previous studies (20-21). Masked to all clinical data, primary graders marked out 1) 158 
the uppermost extent of the vitreous space included in the scan - the “vitreous top”, 159 
2) the internal limiting (ILM) membrane, 3) the inner layer of the RPE, and 4) the 160 
outer layer of the RPE on all the scans. This was done on five sections going 161 
through the central fovea subfield of the Early Treatment Diabetic Retinopathy Study 162 
(ETDRS) grid. The area between lines 1 and 2 was defined as the “vitreous 163 
space”(VIT), whilst the area between 3 and 4 was defined as the “RPE space” 164 
(RPE). The software then calculated the mean intensity values of all image pixels 165 
contained within each space as absolute values. A relative value, the VIT/RPE-166 
Relative Intensity, could then be derived to minimise the potential effects of 167 
confounders such as lens opacities or anterior chamber inflammation (Figure 1).  168 
 169 
Statistical Analyses: 170 
Clinical and imaging data were analyzed with frequency and descriptive statistics. 171 
Snellen visual acuities were converted to LogMAR (logarithm of the minimum angle 172 
of resolution) visual acuity for the purposes of statistical analysis. Spearman’s 173 
correlation was used to assess the relationship between the VIT/RPE-Relative 174 
Intensity and clinical/retinal imaging parameter.  The Mann-Whitney U test was used 175 
in independent samples and Wilcoxon Signed Ranks test in dependent samples. 176 
Statistical analysis was performed using IBM SPSS software version 20.0 for 177 
Windows (SPSS, Inc, Chicago, Illinois, USA). P values < 0.05  were considered 178 
significant. 179 
 180 
  181 
Results 182 
 183 
Baseline Characteristics: 184 
The study included 22 eyes of 22 patients, before and after treatment with STTA. 185 
Their baseline characteristics are listed in Table 1. 186 
 187 
VIT/RPE-Relative Intensity 188 
Treatment with STTA was associated with a significant reduction in OCT-measured 189 
VIT/RPE-Relative Intensity (Figure 2). The mean (SD) VIT/RPE-Relative Intensity 190 
pre-treatment was 0.139 (0.074) vs. 0.053 (0.028) post-treatment (p=3x10-5).  191 
 192 
Mean Central Retinal Thickness 193 
Treatment with STTA was associated with significant reduction in the OCT-194 
measured mean central 1 mm of retinal thickness (CRT). Mean (SD) CRT was 195 
580.5μm (119.4μm) pre-treatment vs 332.7μm (95.4μm) post-treatment (p=2x10-8); 196 
the mean reduction in CRT was 247.7 (95%CI: 189.1-306.3). The correlation 197 
coefficient between VIT/RPE-Relative Intensity and CRT was 0.534 (p=0.011; Figure 198 
3). 199 
 200 
 201 
Visual acuities 202 
Treatment with STTA was associated with significant improvement in visual acuity 203 
(p=0.0001). The number of patients with a visual acuity greater than 6/12 increased 204 
from 1 (4.54%) to 17 (77.3%) with a corresponding reduction in those with 6/12 or 205 
worse from 19 (86.4%) to 5 (22.7%) (Fisher exact test, p=0.0001). The correlation 206 
coefficient between VIT/RPE-Relative Intensity and visual acuity was 0.702 207 
(p=0.0001; Figure 4).  208 
 209 
Discussion 210 
This study provides the first ‘treatment-response’ data to support our proposal 211 
that OCT can be used to provide an objective measure of treatment response in 212 
uveitis based on changes in the vitreous. It builds on our previous feasibility study in 213 
which we demonstrated proof of concept that the VIT/RPE-Relative Intensity could 214 
provide an objective and quantitative measure of vitreous inflammation. Both that 215 
cross-sectional study and a validation study in an independent cohort showed that 216 
the VIT/RPE-Relative Intensity was higher in uveitic eyes with active inflammation 217 
than uveitic eyes without active inflammation or healthy controls, and that it 218 
correlated with the clinical NEI vitreous haze score (17-18).We also showed 219 
association with other markers of disease activity such as visual acuity, AC cells and 220 
AC flare. Importantly the VIT/RPE Relative Intensity was also shown to be a 221 
repeatable measure with high inter-grader reproducibility (17-18). 222 
 223 
 In this study we have demonstrated that the VIT/RPE-Relative Intensity 224 
decreases significantly in response to STTA and that this reduction was associated 225 
with improvement in another measurable sign of disease activity, CMO.  Critically 226 
this study demonstrates VIT/RPE-Relative intensity is sensitive enough to measure 227 
changes in the vitreous undetectable using the clinical NEI Vitreous Haze Score.  As 228 
highlighted by a number of authors, the poor discrimination of the NEI Vitreous Haze 229 
Score at lower levels has led most clinical trials in this field to require subjects to 230 
have a minimum NEI Vitreous Haze Score of 2+ for inclusion. This has significantly 231 
limited enrolment (7-10,22). In an observational study comparing a photographic-232 
based score to the NEI score, Hornbeak noted that had they used the traditional ‘cut-233 
off’ 86% of participants would have been excluded. Although a significant proportion 234 
of that cohort were scored as 0 on the NEI Vitreous Haze Score it cannot be argued 235 
that all these cases were inactive as both the Hornbeak study and our current study 236 
indicate that an appropriately sensitive tool is able to discriminate within this group 237 
(9). Whereas the Hornbeak study was cross-sectional, our longitudinal study is the 238 
first to show a tool capable of detecting change in uveitis activity within these lower 239 
levels of inflammation, even when both the pre-treatment and post-treatment clinical 240 
Vitreous Haze Score was 0.  241 
 242 
There is an urgent need to develop sensitive objective measures of 243 
inflammation in uveitis, for use as endpoints in clinical trials and to inform treatment 244 
decisions in routine clinical practice. The FDA advises that a trial endpoint must be 245 
‘well-defined and reliable’ and recommends that treatment benefit should be a 246 
measure of how a patient “survives, feels or functions”. Other measures that do not 247 
capture these are regarded as “surrogate measures of benefit”. 248 
 249 
All measures of disease activity in uveitis are “surrogate measures”. The FDA 250 
requires a surrogate to be “reasonably likely, based on epidemiologic, therapeutic, 251 
pathophysiologic, or other evidence to predict clinical benefit”., In the context of 252 
developing and assessing surrogate measures for use as trial endpoints in uveitis, 253 
we propose that they must meet two essential criteria: (1) The surrogate should be 254 
‘biologically relevant’ given our understanding of the pathophysiology of the disease; 255 
and (2) The surrogate should be ‘functionally relevant’ with evidence of a 256 
downstream effect on visual function, but recognizing that this effect may be delayed 257 
and indirect. Provided a surrogate satisfies these criteria, it should then be assessed 258 
for  desirable criteria such as objectivity, repeatability, and sensitivity, 259 
 260 
This study provides further evidence of the biological and functional relevance 261 
of VIT/RPE relative intensity..Its biological relevance is demonstrated by its 262 
association with other markers of inflammation such as the central retinal thickness. 263 
Its functional relevance is supported by its correlation with visual recovery, however 264 
it is recognized that this is largely indirect, the primary mechanism of improvement 265 
being the restoration of central macular architecture as the oedema resolves.  266 
 267 
The OCT-derived VIT/RPE-Relative intensity is the first instrument-measured 268 
marker of vitreous inflammation, and is an example of how extended applications of 269 
OCT and other imaging modalities have the potential to revolutionise our approach 270 
to the diagnosis, assessment and management of uveitis. Research into VIT/RPE-271 
Relative intensity levels during the development of CME and its relation to vascular 272 
changes visualized on fluorescein angiography may inform our understanding of the 273 
natural history of this sight-threatening complication, and help guide treatment.. 274 
 275 
Furthermore the sensitivity of this small study to detect a change at a highly 276 
statistically significant level (p = 0.00003), shows how the acceptance of OCT-277 
derived objective indices could transform our approach to effectiveness trials in 278 
uveitis.  .The limitations of our current endpoints in uveitis provide major constraints 279 
to effectiveness trials (7-10,23), which may lead to a trial ‘failing’ (i.e. not meeting its 280 
primary endpoint) even in the presence of an effective therapy. This in turn 281 
discourages further investment, and leads to an absence of high-quality trial data to 282 
inform clinicians, funders and policy makers with regard to main of therapies being 283 
considered for use in uveitis. The high sensitivity and reproducibility of instrument-284 
based measures such as the OCT-derived VIT/RPE relative intensity can provide 285 
endpoints with much higher ’signal:noise’ ratio than current clinical measures 286 
enabling smaller, faster, cheaper trials. Such endpoints can already be adopted as 287 
‘signals’ to inform investment decisions in early phase studies, but their adoption in 288 
later-phase licensing studies will depend on achieving the further validation required 289 
by regulatory bodies such as the FDA.  290 
 291 
Study limitations  292 
This study involves retrospective analysis of longitudinal OCT image sets 293 
obtained from a small number of patients with uveitis and OCT-confirmed CMO. It 294 
therefore has the limitations of a retrospective design, and we acknowledge that 295 
given the nature of this cohort the focus of the clinical assessments at the time will 296 
have been directed towards the CMO, and not on accurate grading of the clinical 297 
vitreous haze. We also note that visual acuity data were recorded as Snellen 298 
measurements rather than the preferred LogMAR notation. It should be noted 299 
however that the primary focus of this paper is on the post-hoc analysis of the OCT 300 
image sets and their change over time, rather than on the associated clinical 301 
changes. 302 
 303 
The design of the study was pragmatic in using scans conducted under 304 
normal macular scanning conditions. We and others have proposed a number of 305 
techniques for optimising the visualisation of vitreous using current Spectral Domain 306 
and emerging technology (8,10, 17-18). Increasing the proportion of the vitreous 307 
which is visualised is likely to improve this technique further, enhancing sensitivity 308 
and repeatability; it also enables anatomic localisation of foci of inflammation within 309 
the vitreous cavity related to the distribution and type of uveitis.  310 
 311 
This study is based on a small cohort, with a range of uveitic diagnoses. This 312 
heterogeneity is common in uveitis studies (8,10), and indeed the consistent 313 
performance of the VIT/RPE relative intensity tool across this range of patients is 314 
very encouraging for its future usefulness is an outcome measure. Critically, despite 315 
its size and heterogeneity, the study achieved its primary endpoint at a high level of 316 
statistical significance . 317 
 318 
A barrier to the potential adoption of our technique as described in this study 319 
is that it is time-consuming, taking around 3-5 minutes per scan. Recently however 320 
we have developed a software package for automation of this process. This custom 321 
software entitled VITreous ANalysis (VITAN) can segment and annotate the scans 322 
automatically, reducing the time taken to derive measures of vitreous reflectivity to a 323 
few seconds per scan, with benefits in speed, cost, and further reduction of 324 
subjectivity or human error in marking the boundaries of anatomical structures (24).  325 
 326 
 To conclude, in this study we have further demonstrated the relevance of the 327 
OCT-derived VIT/RPE-Relative intensity as a quantitative and objective marker of 328 
disease activity and treatment response in uveitis complicated by CME. This first 329 
longitudinal study of this novel OCT parameter is an encouraging step in the 330 
development of sensitive objective OCT-based endpoints for trials of efficacy in 331 
uveitis.   332 
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Tables and figures: 412 
TABLE 1: Baseline Characteristics 413 
Age  47.4 years ( 23y – 74y) 
Gender 
 
Female 
Male 
 
 
17 (77%) 
5 (23%) 
Anatomical Site of Uveitis 
 
Panuveitis 
Intermediate Uveitis 
Anterior Uveitis 
 
 
10 (45%) 
8 (36%) 
4 (18%) 
Aetiology 
 
Idiopathic 
Sarcoidosis 
TINU 
Behcet’s 
Reiter 
VKH 
 
 
14 (64%) 
4 (18%)  
1 (5%) 
1 (5%) 
1 (5%) 
1 (5%) 
AC Cells 
 
 
 
0 
0.5+ 
1+ 
2+ 
3+ 
4+ 
Not available 
6 
6 
4 
4 
0 
0 
2 
AC Flare 
 
0 
0.5+ 
1+ 
2+ 
3+ 
4+ 
Not available 
 
 
12 (54.54%) 
2 (9.09%) 
6 (27.27%) 
0 
0 
0 
2 (9.09%) 
Vitreous haze 
 
0 
0.5+ 
1+ 
2+ 
3+ 
4+ 
Not available 
 
 
15 (68.18%) 
0 
2 (9.09%) 
1 (4.54%) 
0 
0 
4 (18.18%) 
 414 
 415 
416 
Timing of Post-Intervention Review 
Median (range) duration to follow-up 
OCT scan and review post-treatment 
 
7 weeks (4 – 19 weeks) 
 417 
 418 
 419 
Figure 1. Quantitative assessment of the vitreous using OCT 420 
demonstrated in a 47 year old male with intermediate uveitis (A,B) and a 421 
48 year old female with panuveitis (C,D). Both patients were assessed 422 
by standard macular-focussed OCT both before (A,C) and after (B,D) 423 
treatment with Sub-Tenon’s Triamcinolone Acetonide (STTA), with 424 
calculation of the Vitreous/RPE-Relative Intensity (Vit/RPE RI).. 425 
426 
 427 
 428 
Figure 2. VIT/RPE–Relative Intensity before and after treatment with 429 
Sub-Tenon Triamcinolone Acetonide (STTA) for Uveitic Cystoid Macular 430 
Oedema (CMO). 431 
432 
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 434 
Figure 3. Correlation between change in VIT/RPE–Relative intensity and 435 
change in mean central retinal thickness.436 
 437 
 438 
 439 
Figure 4. Correlation between change in VIT/RPE–Relative intensity and 440 
change in visual acuity. 441 
 442 
 443 
